Medtronic, Inc. v. Lohr

The Court began with the presumption that Congress does not displace traditional state police powers, especially in the field of health and safety, absent a clear and manifest purpose. Although § 360k(a) expressly pre-empts some state requirements, its text must be read in light of that presumption and Congress’s purpose.

Medtronic’s interpretation would have given device manufacturers sweeping immunity from state design-defect liability even though the MDA contains no private federal damages action. The Court found it implausible that Congress, in legislation enacted to promote device safety, silently intended to leave injured patients with little or no judicial remedy.

The statutory term “requirement” did not clearly signal an intent to wipe out common-law claims across the board. In context, the MDA’s repeated references to requirements, including the FDA’s authority to exempt some state requirements, suggested a primary concern with specific state statutes and regulations that could conflict with federal device regulation.

The legislative history reinforced this reading. Congress was concerned with avoiding inconsistent regulatory burdens, but nothing in the legislative materials indicated that it meant to abolish traditional product-liability actions. The central purpose of the MDA was to improve medical-device safety, not to immunize manufacturers from liability for defective products.

The § 510(k) process asks whether a new device is substantially equivalent to a device marketed before the MDA, not whether the new device is independently safe and effective. It is far less rigorous than premarket approval, and it ordinarily allows marketing without an FDA safety-and-efficacy determination.

The FDA’s letter to Medtronic made this point explicit: it permitted marketing subject to general controls but stated that it did not constitute FDA approval of the Model 4011 lead. Thus, the FDA did not require the pacemaker lead to have a particular design based on a considered safety judgment.

Congress created the substantial-equivalence route largely to preserve competition with grandfathered devices while the FDA completed its regulatory work. That arrangement maintained the preexisting possibility of state tort litigation; it did not establish a federal design standard that displaced state design-defect law.

Section 360k(a) pre-empts state requirements only when they are “different from, or in addition to” applicable federal requirements. A state-law claim based on a manufacturer’s failure to comply with the same federal duty does not impose a divergent substantive obligation; it reinforces compliance with the federal one.

A negligence claim may require proof of additional state-law elements, such as unreasonable conduct or causation, but those elements narrow the circumstances in which damages are available rather than impose a broader device standard. The availability of damages supplies an additional incentive to comply, not an additional substantive requirement.

The Court gave substantial weight to the FDA’s regulation stating that the MDA does not pre-empt state requirements that are equal to or substantially identical to federal requirements. Because the pleadings could encompass claims that Medtronic violated federal duties, the lower court should not have dismissed the manufacturing and labeling claims wholesale.

The FDA’s pre-emption regulation provides that state requirements are pre-empted only when the FDA has imposed specific counterpart regulations or other specific requirements applicable to a particular device. The MDA and the regulation therefore require a careful comparison between the federal requirement and the state duty asserted.

The good-manufacturing-practice rules and labeling rules relied on by Medtronic were broad, generally applicable rules governing many devices and many aspects of production. They did not embody a particularized federal judgment about the Model 4011 lead’s manufacturing methods or warnings that would be undermined by the Florida claims.

Likewise, Florida’s duties of reasonable care in manufacturing and warning consumers of foreseeable risks were general common-law duties, not device-specific regulations. Such general duties did not threaten to interfere with a specific federal regulatory decision, so the Court reversed the Eleventh Circuit’s ruling that the manufacturing and warning claims were pre-empted.

The Lohrs argued that common-law duties can never count as state requirements under § 360k(a). The Court declined to resolve that broad proposition because doing so was unnecessary once it concluded that the particular design, manufacturing, and warning claims survived.

The Court observed that, given the importance of device-specific federal requirements, it would be rare for a common-law judgment to establish a substantive requirement for a particular device. A future case involving such a judgment might raise the question, but it was not presented here.